Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

NCT00144612 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Juvenile Idiopathic Arthritis

Interventions

DRUG: MRA(Tocilizumab)

Sponsor

Chugai Pharmaceutical